<table class="ccotable" cellpadding="0" cellspacing="0" width="500"> <thead align="left"><tr><th>
HER2 Assessment
</th> <th>
Patients, n
</th> <th colspan="2">
AC → P
</th> <th colspan="2">
AC → PT
</th> <th>
Risk Ratio
(95% CI)
</th> <th>
P Value
</th> </tr> <tr> <th>
</th> <th>
</th> <th>
n
</th> <th>
Events
</th> <th>
n
</th> <th>
Events
</th> <th>
</th> <th>
</th> </tr> </thead> <tbody> <tr> <td> FISH positive
</td> <td>
1588
</td> <td>
789
</td> <td>
160
</td> <td>
799
</td> <td>
85
</td> <td>
0.47
(0.36-0.61)
</td> <td>
< .0001
</td> </tr> <tr class="alternate"> <td> FISH negative
</td> <td>
207
</td> <td>
114
</td> <td>
23
</td> <td>
93
</td> <td>
8
</td> <td>
0.40
(0.18-0.89)
</td> <td>
.026
</td> </tr> <tr> <td> IHC positive (3+)
</td> <td>
1488
</td> <td>
740
</td> <td>
151
</td> <td>
748
</td> <td>
82
</td> <td>
0.48
(0.37-0.63)
</td> <td>
< .0001
</td> </tr> <tr class="alternate"> <td> IHC negative
(0, 1+, 2+)
</td> <td>
299
</td> <td>
161
</td> <td>
32
</td> <td>
138
</td> <td>
10
</td> <td>
0.32
(0.16-0.65)
</td> <td>
.0017
</td> </tr> <tr> <td> FISH and IHC negative
</td> <td>
174
</td> <td>
92
</td> <td>
20
</td> <td>
82
</td> <td>
7
</td> <td>
0.34
(0.14-0.80)
</td> <td>
.014
</td> </tr> </tbody> </table>
AC → P; doxorubicin, cyclophosphamide followed by paclitaxel; AC → PT; doxorubicin, cyclophosphamide followed by trastuzumab and paclitaxel.- No significant interaction between DFS benefit from trastuzumab and
- HER2 protein level
- HER2 gene copy number
References
1. Paik S, Kim C, Jeong J, et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: central testing results from NSABP B-31. Program and abstracts of the 43rd American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, Illinois. Abstract 511.
2. Romond E, Perez EA, Bryant J, et al. Docetaxel and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2-positive operative breast cancer: combined analysis of NSABP-B-31 and NCCTG-N9831. Program and abstracts of the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Florida.